Obama Faces Widespread Public Distrust on Iran Deal
President Obama will try to drum up support for the U.S.-Iran nuclear deal Wednesday afternoon at a news conference. But with widespread public disdain and distrust of Iran, Obama may have trouble convincing Americans of the wisdom of dealing with a long-time arch enemy in the Middle East.
The U.S. and Iran on Tuesday announced an agreement that would potentially block Iran’s development of a nuclear weapon for at least a decade while lifting international economic sanctions against Tehran. However, a new AP-GfK poll that was conducted just ahead of the announcement found that Americans only narrowly back diplomatic relations with the hardline Islamic government, and many want to see the sanctions kept in place.
Related: The 8 Most Important Things to Know About the Iran Nuclear Deal
Just 51 percent of those interviewed said the U.S. should have diplomatic relations with Iran while 45 percent said it shouldn’t. At the same time, 77 percent of those interviewed said the harsh U.S. and international economic sanctions against Iran should be preserved at current levels or even increased.
Only 12 percent of those interviewed thought sanctions should be decreased and seven percent said they should be eliminated altogether.
The public’s wariness and distrust of dating back to the 1979 Iranian revolution and U.S. hostage crisis matches the reception the nuclear agreement has received on Capitol Hill where most Republicans and some Democrats say they fear Obama has conceded too much to a country that has fomented terrorist activities throughout the Middle East and has repeatedly vowed to destroy Israel.
Fifty-six percent of Americans consider Iran to be an enemy, according to the poll conducted last Thursday through Monday, while an additional 31 percent consider Iran to be unfriendly but not an enemy. More than 70 percent of Republicans, half of all independents and 45 percent of Democrats described Iran as the enemy.
Related: Clinton Cautious in Her Praise of a Nuclear Deal She Helped to Orchestrate
Before the agreement was announced, six in ten Americans said they disapproved of Obama's handling of the U.S. relationship with Iran, while just over a third approved.
Obama is likely to prevail in pushing the nuclear non-proliferation agreement through Congress over the next two months, despite near-unanimous opposition from Senate Majority Leader Mitch McConnell, House Speaker John Boehner and other leaders and rank and file Republicans. Still, he will need to hold in place at least 34 of the 46 Democrats in the Senate to create a veto-proof firewall in the event Republicans push through a resolution of disapproval of the nuclear deal.
That means that Obama cannot afford any more than 12 Democratic defections to keep the agreement alive. Yesterday, Obama and Vice President Joe Biden began working the phones to shore up support on Capitol Hill, and the president will continue that effort during this afternoon’s White House press conference.
During an interview yesterday with Tom Friedman of The New York Times, Obama stressed that the deal prevented a pathway for Iran to develop a nuclear weapon while making it clear he shared Americans’ distrust of the Iranian government and had limited expectations of improved relations down the road.
Related: Iran Agrees to Limit Nuclear Weapon in Historic Deal
When announcing the deal yesterday, Obama said, “This deal is not built on trust -- it's built on verification…. We will, for the first time, be in a position to verify that Iran is meeting all of these commitments. International nuclear inspectors will have access to Iran's nuclear program -- where necessary, when necessary. This is the most comprehensive and intrusive verification regime that we have ever negotiated. If Iran tries to divert raw materials to covert facilities, inspectors will be able to access any suspicious locations.”
Tax Refunds Rebound
Smaller refunds in the first few weeks of the current tax season were shaping up to be a political problem for Republicans, but new data from the IRS shows that the value of refund checks has snapped back and is now running 1.3 percent higher than last year. The average refund through February 23 last year was $3,103, while the average refund through February 22 of 2019 was $3,143 – a difference of $40. The chart below from J.P. Morgan shows how refunds performed over the last 3 years.
Number of the Day: $22 Trillion
The total national debt surpassed $22 trillion on Monday. Total public debt outstanding reached $22,012,840,891,685.32, to be exact. That figure is up by more than $1.3 trillion over the past 12 months and by more than $2 trillion since President Trump took office.
Chart of the Week: The Soaring Cost of Insulin
The cost of insulin used to treat Type 1 diabetes nearly doubled between 2012 and 2016, according to an analysis released this week by the Health Care Cost Institute. Researchers found that the average point-of-sale price increased “from $7.80 a day in 2012 to $15 a day in 2016 for someone using an average amount of insulin (60 units per day).” Annual spending per person on insulin rose from $2,864 to $5,705 over the five-year period. And by 2016, insulin costs accounted for nearly a third of all heath care spending for those with Type 1 diabetes (see the chart below), which rose from $12,467 in 2012 to $18,494.
Chart of the Day: Shutdown Hits Like a Hurricane
The partial government shutdown has hit the economy like a hurricane – and not just metaphorically. Analysts at the Committee for a Responsible Federal Budget said Tuesday that the shutdown has now cost the economy about $26 billion, close to the average cost of $27 billion per hurricane calculated by the Congressional Budget Office for storms striking the U.S. between 2000 and 2015. From an economic point of view, it’s basically “a self-imposed natural disaster,” CRFB said.
Chart of the Week: Lowering Medicare Drug Prices
The U.S. could save billions of dollars a year if Medicare were empowered to negotiate drug prices directly with pharmaceutical companies, according to a paper published by JAMA Internal Medicine earlier this week. Researchers compared the prices of the top 50 oral drugs in Medicare Part D to the prices for the same drugs at the Department of Veterans Affairs, which negotiates its own prices and uses a national formulary. They found that Medicare’s total spending was much higher than it would have been with VA pricing.
In 2016, for example, Medicare Part D spent $32.5 billion on the top 50 drugs but would have spent $18 billion if VA prices were in effect – or roughly 45 percent less. And the savings would likely be larger still, Axios’s Bob Herman said, since the study did not consider high-cost injectable drugs such as insulin.
